康泰医学(300869) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥368,699,882.77, representing a 101.21% increase compared to ¥183,239,114.02 in the same period last year[6] - Net profit attributable to shareholders was ¥170,052,052.02, up 131.97% from ¥73,307,986.92 year-on-year[6] - Basic earnings per share rose to ¥0.4232, reflecting a 131.89% increase from ¥0.1825 in the previous year[6] - Operating profit for the quarter was ¥188,205,059.30, up from ¥81,569,879.56, reflecting a growth of 130.5% year-over-year[23] - Net profit attributable to the parent company was ¥170,052,052.02, compared to ¥73,307,986.92 in Q1 2022, marking an increase of 132.5%[23] - The total comprehensive income for the quarter was ¥169,492,486.63, up from ¥72,474,343.11, an increase of 133.4% year-over-year[23] Cash Flow - The net cash flow from operating activities was ¥101,516,355.63, a significant increase of 185.55% compared to ¥35,551,530.90 in Q1 2022[6] - Total cash inflow from operating activities was ¥410,840,410.94, up from ¥220,255,932.02, indicating a growth of about 86% year-over-year[27] - Cash outflow from operating activities increased to ¥309,324,055.31 from ¥184,704,401.12, reflecting a rise of approximately 67%[27] - The net cash flow from investing activities was -¥159,393,812.47, compared to -¥27,462,747.05 in the previous year, showing a significant increase in cash outflow[27] - Cash inflow from financing activities totaled ¥322,376,199.40, while cash outflow was ¥533,152,263.57, resulting in a net cash flow of -¥210,776,064.17 for Q1 2023[28] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,686,584,058.64, a slight decrease of 1.24% from ¥3,732,805,832.45 at the end of the previous year[6] - Total liabilities decreased to ¥1,588,688,602.38 from ¥1,804,472,003.19, representing a decline of about 11.9%[20] - The company's equity attributable to shareholders increased by 8.79% to ¥2,097,895,456.26 from ¥1,928,333,829.26 at the end of the previous year[6] Shareholder Information - The total number of common shareholders at the end of the reporting period is 43,477[12] - The largest shareholder, Hu Kun, holds 46.84% of the shares, totaling 188,189,252 shares[12] - The second-largest shareholder, Wang Guigang, owns 12.72% of the shares, amounting to 51,126,226 shares[12] Expenses - The company reported a significant increase in sales expenses, which rose by 258.01% to ¥34,329,659.15 due to higher platform and technical service fees[10] - The company experienced a 69.12% increase in tax liabilities, amounting to ¥60,207,358.78, driven by higher sales and profit levels[10] - Research and development expenses amounted to ¥25,005,015.83, which is an increase of 28.5% from ¥19,456,247.07 in the previous year[22] - Employee compensation payments rose to ¥59,520,945.56 from ¥42,830,540.37, reflecting an increase of approximately 39% year-over-year[27] Inventory and Receivables - The company reported accounts receivable of approximately ¥161.74 million, slightly up from ¥160.75 million at the beginning of the year[18] - Inventory at the end of the reporting period is approximately ¥514.44 million, an increase from ¥430.24 million at the beginning of the year[18] Cash and Cash Equivalents - The company's cash and cash equivalents at the end of the first quarter are approximately ¥1.13 billion, down from ¥1.39 billion at the beginning of the year[18] - The ending balance of cash and cash equivalents was ¥1,127,658,903.27, down from ¥1,387,323,098.06 at the beginning of the quarter, indicating a decrease of approximately 19%[28] Restricted Shares - The company has a total of 241,722,866 restricted shares, with 16,199,656 shares released during the period[16] - The company plans to unlock certain restricted shares based on executive lock-up conditions[15]